Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers

Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers

Backgrounds & Aims: The efficacy of immune checkpoint inhibitor (ICI) therapy for liver cancer remains limited. As the hypoxic liver environment regulates adenosine signaling, we tested the efficacy of adenosine A2a receptor (A2aR) inhibition in combination with ICI treatment in murine model...

Full description

Bibliographic Details
Main Authors: Yuta Myojin, Justin D. McCallen, Chi Ma, Kylynda C. Bauer, Benjamin Ruf, Mohamed-Reda Benmebarek, Benjamin L. Green, Simon Wabitsch, John C. McVey, Claude Fu, Changqing Xie, Tim F. Greten
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:JHEP Reports
Subjects:
Liver cancer
immunotherapy
adenosine receptor
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923002902

Similar Items

Similar Items